# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

> **NCT00871507** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 25 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** JNJ-38431055 Dose 1
- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Placebo
- **DRUG:** JNJ-38431055 Dose 2

## Key facts

- **NCT ID:** NCT00871507
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871507, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00871507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*